Scholarlink

<p>Screening of heart failure (HF) remains suboptimal. However, vocal biomarkers are an emerging tool to screen for HF and predict adverse outcomes. This article is a literature review of the current evidence, exploring the use of vocal biomarkers to screen for HF and predict hospitalisation and mortality. Voice may be utilised as a time-efficient method for the screening of HF, risk stratification, and monitoring of disease progression. Vocal biomarkers such as pause ratio and artificial neural networks can screen for HF accurately in a case-control setting. Other vocal markers like maximum phonation time, creak percent are useful to monitor disease progression. Vocal biomarkers appear to match current predictors of one-year mortality, HF related decompensation and hospitalisation. The integration of vocal biomarkers assessment in HF healthcare is promising across primary and secondary care settings. Key challenges including health data protection, regulatory compliance, and user acceptance must be addressed before these tools can be fully integrated into HF clinical care pathway.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Voice recognition as an innovative method to identify and monitor heart failure – a review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月16日

查看全文
  • Amy S. Fuller,
  • Nduka C Okwose,
  • Sarah J. Charman,
  • Alban E. Voppel,
  • Renae J. Stefanetti,
  • Amy Groenewegen,
  • Annamaria Del Franco,
  • Maria Tafelmeier,
  • Andrej Preveden,
  • Aleksandra Milovancev,
  • Duncan Edwards,
  • Anne P. Nelissen,
  • Fausto Barlocco,
  • Alessandra Fornaro,
  • Jose Luis Zamorano,
  • Massimo Milli,
  • Laura Sasso,
  • Giulia Taborchi,
  • Simone Bartolini,
  • Serena Fatucchi,
  • Prithwish Banerjee,
  • Guy A. MacGowan,
  • Oscar Fernandez,
  • Marta Jimenez-Blanco Bravo,
  • Lars S. Maier,
  • Iacopo Olivotto,
  • Frans H. Rutten,
  • Jonathan Mant,
  • Lazar Velicki,
  • Petar M. Seferovic,
  • Nenad Filipovic,
  • Djordje G. Jakovljevic

摘要

Screening of heart failure (HF) remains suboptimal. However, vocal biomarkers are an emerging tool to screen for HF and predict adverse outcomes. This article is a literature review of the current evidence, exploring the use of vocal biomarkers to screen for HF and predict hospitalisation and mortality. Voice may be utilised as a time-efficient method for the screening of HF, risk stratification, and monitoring of disease progression. Vocal biomarkers such as pause ratio and artificial neural networks can screen for HF accurately in a case-control setting. Other vocal markers like maximum phonation time, creak percent are useful to monitor disease progression. Vocal biomarkers appear to match current predictors of one-year mortality, HF related decompensation and hospitalisation. The integration of vocal biomarkers assessment in HF healthcare is promising across primary and secondary care settings. Key challenges including health data protection, regulatory compliance, and user acceptance must be addressed before these tools can be fully integrated into HF clinical care pathway.